Polyclonal Antibody to Janus Kinase 3 (JAK3)
| Code | Size | Price |
|---|
| PAF493Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAF493Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAF493Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAF493Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
JAKL; L-JAK; LJAK; A Protein Tyrosine Kinase,Leukocyte; Leukocyte janus kinase; Tyrosine-protein kinase JAK3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Janus Kinase 3
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 1-5ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml<br/>Immunohistochemistry in paraffin section: 5-20ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Janus Kinase 3 (JAK3) | RPF493Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||